literature data on its likely competitors can provide insight into
disease progression, effectiveness of current marketed therapies, and
tools for exploring the potential of new treatments.
-- Dosing Strategies of Drugs with Narrow Therapeutic Windows: A Simple
Approach to Determine Trade-off Between Efficacy and Toxicity. As part
of a poster session on pharmacometric tools and techniques, Dr. Samer
Mouksassi, associate scientist, Reporting and Analysis Services, will
describe research on how modeling and simulation methods have been
used to determine trade-offs between efficacy and toxicity in order to
design better dosing strategies.
"We look forward to sharing examples of strategic applications of modeling and simulation with industry colleagues and to discussing specific elements of our technology vision for the future of model-based drug development," added Mr. O'Connor.
A complete listing of Pharsight's ACoP presentations and poster contributions is available at http://www.pharsight.com/events/events_conferences.php.
The ACoP is organized and delivered by a cross-section of industry, academic and regulatory experts in the interdisciplinary science of pharmacometrics who also represent several regional U.S. modeling and simulation meetings and associations. Additional information about ACoP can be found at http://mosaicnj.com/acop/index.php.
About Pharsight Corporation
Pharsight Corporation develops and markets integrated products and
services that enable pharmaceutical and biotechnology companies to achieve
significant and enduring improvements in the development and use of
therapeutic products. Pharsight's goal is
|SOURCE Pharsight Corporation|
Copyright©2008 PR Newswire.
All rights reserved